NICE backs NHS use of Lilly’s Olumiant in eczema
Oral JAK inhibitor approved to treat moderate-to-severe atopic eczema in adults
Read More
Tag: Olumiant
Lilly to test Olumiant, LY3127804 against COVID-19
The RA drug Olumiant will be assessed in patients hospitalised with the virus
Read More
Lilly’s atopic dermatitis drug hits endpoints
Both the 4mg and 2mg dosages met the trials’ primary endpoint in BREEZE-AD1 and BREEZE-AD2.
Read More
Lilly to progress Olumiant into PhIII for lupus
The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).
Read More
US approves Lilly/Incyte’s Olumiant
As expected, US regulators have approved the lower dose of Eli Lilly/Incyte’s once-daily JAK inhibitor Olumiant as treatment for rheumatoid arthritis (RA).
Read More
NICE backs Lilly’s JAK inhibitor Olumiant for RA
A novel treatment option for some patients with rheumatoid arthritis (RA) could soon be routinely available on the NHS, after cost regulators ruled Eli Lilly’s Olumiant to be cost-effective with the inclusion of a confidential patient access scheme.
Read More
Lilly/Incyte’s Olumiant bags first approval with EU nod
Eli Lilly’s Olumiant has picked up its first regulatory approval with a nod from the European Commission to treat moderate-to-severe active rheumatoid arthritis.
Read More
December CHMP decisions bring year’s total approvals to 81
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed seven new medicines for approval at its December meeting, bringing the total number recommended during the year to 81, dropping from 2015’s tally of 93.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
